Edelman MJ - Search Results

1

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.

Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Nemieboka N, Chung EJ, Van Echo D. Edelman MJ, et al. Cancer Chemother Pharmacol. 2003 May;51(5):439-44. doi: 10.1007/s00280-003-0580-5. Epub 2003 Mar 12. Cancer Chemother Pharmacol. 2003. PMID: 12736763 Clinical Trial.

2

Phase I study of docetaxel and topotecan in patients with solid tumors.

Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA. Tkaczuk KH, et al. Among authors: edelman mj. Cancer Chemother Pharmacol. 2000;46(6):442-8. doi: 10.1007/s002800000180. Cancer Chemother Pharmacol. 2000. PMID: 11138457 Clinical Trial.

3

Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.

Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J. Edelman MJ, et al. Clin Cancer Res. 2007 May 1;13(9):2667-74. doi: 10.1158/1078-0432.CCR-06-1832. Clin Cancer Res. 2007. PMID: 17473198 Clinical Trial.

4

Advanced non-small cell lung cancer.

Edelman MJ, Khanwani SL. Edelman MJ, et al. Curr Treat Options Oncol. 2001 Feb;2(1):51-62. doi: 10.1007/s11864-001-0016-6. Curr Treat Options Oncol. 2001. PMID: 12057140 Review.

5

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Chiappori A, et al. Among authors: edelman mj. J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027. J Thorac Oncol. 2014. PMID: 24346101 Free PMC article. Clinical Trial.

6

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobbru J. Edelman MJ, et al. Cancer Chemother Pharmacol. 2016 Nov;78(5):959-967. doi: 10.1007/s00280-016-3148-x. Epub 2016 Sep 12. Cancer Chemother Pharmacol. 2016. PMID: 27620207 Clinical Trial.

7

Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.

Edelman MJ, Quam H, Mullins B. Edelman MJ, et al. Cancer Chemother Pharmacol. 2001 Aug;48(2):141-4. doi: 10.1007/s002800000273. Cancer Chemother Pharmacol. 2001. PMID: 11561780

8

The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.

Balcer-Kubiczek EK, Attarpour M, Edelman MJ. Balcer-Kubiczek EK, et al. Among authors: edelman mj. Cancer Chemother Pharmacol. 2007 May;59(6):781-7. doi: 10.1007/s00280-006-0333-3. Epub 2006 Sep 7. Cancer Chemother Pharmacol. 2007. PMID: 16957930

9

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.

Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Edelman MJ, et al. Cancer. 2001 Jul 1;92(1):146-52. doi: 10.1002/1097-0142(20010701)92:1<146::aid-cncr1302>3.0.co;2-n. Cancer. 2001. PMID: 11443620 Clinical Trial.

10

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.

Lara PN Jr, Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, Edelman MJ. Lara PN Jr, et al. Among authors: edelman mj. Cancer. 2004 Jan 1;100(1):82-8. doi: 10.1002/cncr.11866. Cancer. 2004. PMID: 14692027 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240 results

Search Page

Filters